James R Patrinely1, Laura X Baker1, Elizabeth J Davis2, Haocan Song3, Fei Ye3, Douglas B Johnson2. 1. School of Medicine, Vanderbilt University, Nashville, Tennessee, USA. 2. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. 3. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Abstract
BACKGROUND: Greater than one-half of patients with melanoma who are treated with antibodies blocking programmed cell death protein 1 receptor (anti-PD-1) experience disease progression. The objective of the current study was to identify prognostic factors and outcomes in patients with metastatic melanoma that progressed while they were receiving anti-PD-1 therapy. METHODS: The authors evaluated 383 consecutively treated patients who received anti-PD-1 for advanced melanoma between 2009 and 2019. Patient and disease characteristics at baseline and at the time of progression, subsequent therapies, objective response rate (ORR), overall survival, and progression-free survival were assessed. RESULTS: Of 383 patients, 247 experienced disease progression. The median survival after progression was 6.8 months. There was no difference in survival noted after disease progression based on primary tumor subtype, receipt of prior therapy, or therapy type. However, significantly improved survival after disease progression correlated with clinical features at the time of progression, including normal lactate dehydrogenase, more favorable metastatic stage (American Joint Committee on Cancer eighth edition stage IV M1a vs M1b, M1c, or M1d), mutation status (NRAS or treatment-naive BRAF V600 vs BRAF/NRAS wild-type or treatment-experienced BRAF-mutant), decreasing tumor bulk, and progression at solely existing lesions. After progression, approximately 54.3% of patients received additional systemic therapy. A total of 41 patients received BRAF/MEK inhibition (ORR of 58.6%, including 70.4% for BRAF/MEK-naive patients), 30 patients received ipilimumab (ORR of 0%), and 11 patients received ipilimumab plus nivolumab (ORR of 27.3%). CONCLUSIONS: The current study identified prognostic factors in advanced melanoma for patients who experienced disease progression while receiving anti-PD-1, including lactate dehydrogenase, stage of disease, site of disease progression, tumor size, and mutation status.
BACKGROUND: Greater than one-half of patients with melanoma who are treated with antibodies blocking programmed cell death protein 1 receptor (anti-PD-1) experience disease progression. The objective of the current study was to identify prognostic factors and outcomes in patients with metastatic melanoma that progressed while they were receiving anti-PD-1 therapy. METHODS: The authors evaluated 383 consecutively treated patients who received anti-PD-1 for advanced melanoma between 2009 and 2019. Patient and disease characteristics at baseline and at the time of progression, subsequent therapies, objective response rate (ORR), overall survival, and progression-free survival were assessed. RESULTS: Of 383 patients, 247 experienced disease progression. The median survival after progression was 6.8 months. There was no difference in survival noted after disease progression based on primary tumor subtype, receipt of prior therapy, or therapy type. However, significantly improved survival after disease progression correlated with clinical features at the time of progression, including normal lactate dehydrogenase, more favorable metastatic stage (American Joint Committee on Cancer eighth edition stage IV M1a vs M1b, M1c, or M1d), mutation status (NRAS or treatment-naive BRAF V600 vs BRAF/NRAS wild-type or treatment-experienced BRAF-mutant), decreasing tumor bulk, and progression at solely existing lesions. After progression, approximately 54.3% of patients received additional systemic therapy. A total of 41 patients received BRAF/MEK inhibition (ORR of 58.6%, including 70.4% for BRAF/MEK-naive patients), 30 patients received ipilimumab (ORR of 0%), and 11 patients received ipilimumab plus nivolumab (ORR of 27.3%). CONCLUSIONS: The current study identified prognostic factors in advanced melanoma for patients who experienced disease progression while receiving anti-PD-1, including lactate dehydrogenase, stage of disease, site of disease progression, tumor size, and mutation status.
Authors: Henry T Quach; Anna K Dewan; Elizabeth J Davis; Kristin K Ancell; Run Fan; Fei Ye; Douglas B Johnson Journal: JAMA Oncol Date: 2019-06-01 Impact factor: 31.777
Authors: James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski; Christopher D Lao; C Lance Cowey; Dirk Schadendorf; John Wagstaff; Reinhard Dummer; Pier F Ferrucci; Michael Smylie; David Hogg; Andrew Hill; Ivan Márquez-Rodas; John Haanen; Massimo Guidoboni; Michele Maio; Patrick Schöffski; Matteo S Carlino; Céleste Lebbé; Grant McArthur; Paolo A Ascierto; Gregory A Daniels; Georgina V Long; Lars Bastholt; Jasmine I Rizzo; Agnes Balogh; Andriy Moshyk; F Stephen Hodi; Jedd D Wolchok Journal: N Engl J Med Date: 2019-09-28 Impact factor: 91.245
Authors: Douglas B Johnson; Eirini Pectasides; Emily Feld; Fei Ye; Shilin Zhao; Romany Johnpulle; Ryan Merritt; David F McDermott; Igor Puzanov; Donald Lawrence; Jeffrey A Sosman; Elizabeth Buchbinder; Ryan J Sullivan Journal: J Immunother Date: 2017-01 Impact factor: 4.456
Authors: Richard W Joseph; Jeroen Elassaiss-Schaap; Richard Kefford; Wen-Jen Hwu; Jedd D Wolchok; Anthony M Joshua; Antoni Ribas; F Stephen Hodi; Omid Hamid; Caroline Robert; Adil Daud; Roxana Dronca; Peter Hersey; Jeffrey S Weber; Amita Patnaik; Dinesh P de Alwis; Andrea Perrone; Jin Zhang; S Peter Kang; Scot Ebbinghaus; Keaven M Anderson; Tara C Gangadhar Journal: Clin Cancer Res Date: 2018-04-23 Impact factor: 12.531
Authors: Douglas B Johnson; Garrett M Frampton; Matthew J Rioth; Erik Yusko; Yaomin Xu; Xingyi Guo; Riley C Ennis; David Fabrizio; Zachary R Chalmers; Joel Greenbowe; Siraj M Ali; Sohail Balasubramanian; James X Sun; Yuting He; Dennie T Frederick; Igor Puzanov; Justin M Balko; Justin M Cates; Jeffrey S Ross; Catherine Sanders; Harlan Robins; Yu Shyr; Vincent A Miller; Philip J Stephens; Ryan J Sullivan; Jeffrey A Sosman; Christine M Lovly Journal: Cancer Immunol Res Date: 2016-09-26 Impact factor: 11.151
Authors: Jeffrey E Gershenwald; Richard A Scolyer; Kenneth R Hess; Vernon K Sondak; Georgina V Long; Merrick I Ross; Alexander J Lazar; Mark B Faries; John M Kirkwood; Grant A McArthur; Lauren E Haydu; Alexander M M Eggermont; Keith T Flaherty; Charles M Balch; John F Thompson Journal: CA Cancer J Clin Date: 2017-10-13 Impact factor: 508.702
Authors: April A N Rose; Susan M Armstrong; David Hogg; Marcus O Butler; Samuel D Saibil; Diana P Arteaga; Thiago Pimentel Muniz; Deirdre Kelly; Danny Ghazarian; Ian King; Zaid Saeed Kamil; Kendra Ross; Anna Spreafico Journal: J Immunother Cancer Date: 2021-01 Impact factor: 13.751
Authors: Evelyn de Groot; Sruthy Varghese; Lin Tan; Barbara Knighton; Mary Sobieski; Nghi Nguyen; Yong Sung Park; Reid Powell; Philip L Lorenzi; Bin Zheng; Clifford Stephan; Y N Vashisht Gopal Journal: Cancer Metab Date: 2022-02-22
Authors: Julia Lai-Kwon; Brooke Kelly; Sarah Lane; Rebecca Biviano; Iris Bartula; Frank Brennan; Ingrid Kivikoski; Jake Thompson; Haryana M Dhillon; Alexander Menzies; Georgina V Long Journal: Support Care Cancer Date: 2022-09-22 Impact factor: 3.359
Authors: Gabriela Marsavela; Ashleigh C McEvoy; Michelle R Pereira; Anna L Reid; Zeyad Al-Ogaili; Lydia Warburton; Muhammad A Khattak; Afaf Abed; Tarek M Meniawy; Michael Millward; Melanie R Ziman; Leslie Calapre; Elin S Gray Journal: Br J Cancer Date: 2021-08-09 Impact factor: 7.640